154 related articles for article (PubMed ID: 9056020)
1. Comparison of the in vitro activities of Bay 12-8039, a new quinolone, and other antimicrobials against clinically important anaerobes.
Aldridge KE; Ashcraft DS
Antimicrob Agents Chemother; 1997 Mar; 41(3):709-11. PubMed ID: 9056020
[TBL] [Abstract][Full Text] [Related]
2. Bay 12-8039, a new 8-methoxy-quinolone: comparative in-vitro activity with nine other antimicrobials against anaerobic bacteria.
MacGowan AP; Bowker KE; Holt HA; Wootton M; Reeves DS
J Antimicrob Chemother; 1997 Oct; 40(4):503-9. PubMed ID: 9372419
[TBL] [Abstract][Full Text] [Related]
3. In vitro activity of Bay 12-8039, a new 8-methoxyquinolone.
Fass RJ
Antimicrob Agents Chemother; 1997 Aug; 41(8):1818-24. PubMed ID: 9257770
[TBL] [Abstract][Full Text] [Related]
4. In vitro activity of BAY 12-8039, a new fluoroquinolone.
Woodcock JM; Andrews JM; Boswell FJ; Brenwald NP; Wise R
Antimicrob Agents Chemother; 1997 Jan; 41(1):101-6. PubMed ID: 8980763
[TBL] [Abstract][Full Text] [Related]
5. In vitro activity of Bay 12-8039, a new 8-methoxyquinolone, compared to the activities of 11 other oral antimicrobial agents against 390 aerobic and anaerobic bacteria isolated from human and animal bite wound skin and soft tissue infections in humans.
Goldstein EJ; Citron DM; Hudspeth M; Hunt Gerardo S; Merriam CV
Antimicrob Agents Chemother; 1997 Jul; 41(7):1552-7. PubMed ID: 9210683
[TBL] [Abstract][Full Text] [Related]
6. Comparative in vitro activity of BAY 12-8039 and five other antimicrobial agents against anaerobic bacteria.
Edlund C; Sabouri S; Nord CE
Eur J Clin Microbiol Infect Dis; 1998 Mar; 17(3):193-5. PubMed ID: 9665302
[TBL] [Abstract][Full Text] [Related]
7. Comparative activity of moxifloxacin in vitro against obligately anaerobic bacteria.
Ackermann G; Schaumann R; Pless B; Claros MC; Goldstein EJ; Rodloff AC
Eur J Clin Microbiol Infect Dis; 2000 Mar; 19(3):228-32. PubMed ID: 10795599
[TBL] [Abstract][Full Text] [Related]
8. In vitro activity of the new quinolone BAY y 3118 against anaerobic bacteria.
Nord CE; Lindmark A; Persson I
Eur J Clin Microbiol Infect Dis; 1993 Aug; 12(8):640-2. PubMed ID: 8223667
[TBL] [Abstract][Full Text] [Related]
9. Increased activity of a new chlorofluoroquinolone, BAY y 3118, compared with activities of ciprofloxacin, sparfloxacin, and other antimicrobial agents against anaerobic bacteria.
Aldridge KE
Antimicrob Agents Chemother; 1994 Jul; 38(7):1671-4. PubMed ID: 7979307
[TBL] [Abstract][Full Text] [Related]
10. Antipneumococcal activity of BAY 12-8039, a new quinolone, compared with activities of three other quinolones and four oral beta-lactams.
Visalli MA; Jacobs MR; Appelbaum PC
Antimicrob Agents Chemother; 1997 Dec; 41(12):2786-9. PubMed ID: 9420061
[TBL] [Abstract][Full Text] [Related]
11. Comparison of the antibacterial activities of the quinolones Bay 12-8039, gatifloxacin (AM 1155), trovafloxacin, clinafloxacin, levofloxacin and ciprofloxacin.
Bauernfeind A
J Antimicrob Chemother; 1997 Nov; 40(5):639-51. PubMed ID: 9421311
[TBL] [Abstract][Full Text] [Related]
12. Comparative in vitro activities of trovafloxacin (CP 99,219) and other antimicrobials against clinically significant anaerobes.
Aldridge KE; Ashcraft D; Bowman KA
Antimicrob Agents Chemother; 1997 Feb; 41(2):484-7. PubMed ID: 9021215
[TBL] [Abstract][Full Text] [Related]
13. Quinolone activity against anaerobes.
Appelbaum PC
Drugs; 1999; 58 Suppl 2():60-4. PubMed ID: 10553708
[TBL] [Abstract][Full Text] [Related]
14. In vitro activities of moxifloxacin against 900 aerobic and anaerobic surgical isolates from patients with intra-abdominal and diabetic foot infections.
Edmiston CE; Krepel CJ; Seabrook GR; Somberg LR; Nakeeb A; Cambria RA; Towne JB
Antimicrob Agents Chemother; 2004 Mar; 48(3):1012-6. PubMed ID: 14982797
[TBL] [Abstract][Full Text] [Related]
15. In vitro activity of the new quinolone moxifloxacin (Bay 12-8039) against resistant gram-positive clinical isolates.
Alcalá L; Cercenado E; García-Garrote F; Bouza E
Diagn Microbiol Infect Dis; 1999 Jan; 33(1):27-31. PubMed ID: 9990472
[TBL] [Abstract][Full Text] [Related]
16. In vitro activity of Bay Y3118 against anaerobic bacteria.
Wexler HM; Molitoris E; Finegold SM
Antimicrob Agents Chemother; 1993 Nov; 37(11):2509-13. PubMed ID: 8285647
[TBL] [Abstract][Full Text] [Related]
17. Comparative in vitro antimicrobial activity of a novel quinolone, garenoxacin, against aerobic and anaerobic microbial isolates recovered from general, vascular, cardiothoracic and otolaryngologic surgical patients.
Edmiston CE; Krepel CJ; Kehl KS; Seabrook GR; Somberg LB; Almassi GH; Smith TL; Loehrl TA; Brown KR; Lewis BD; Towne JB
J Antimicrob Chemother; 2005 Nov; 56(5):872-8. PubMed ID: 16186167
[TBL] [Abstract][Full Text] [Related]
18. In vitro activity of a new 8-methoxyquinolone, BAY 12-8039, against Chlamydia pneumoniae.
Roblin PM; Hammerschlag MR
Antimicrob Agents Chemother; 1998 Apr; 42(4):951-2. PubMed ID: 9559818
[TBL] [Abstract][Full Text] [Related]
19. In vitro activities of three of the newer quinolones against anaerobic bacteria.
Wexler HM; Molitoris E; Finegold SM
Antimicrob Agents Chemother; 1992 Jan; 36(1):239-43. PubMed ID: 1317149
[TBL] [Abstract][Full Text] [Related]
20. Comparative activities of clinafloxacin, grepafloxacin, levofloxacin, moxifloxacin, ofloxacin, sparfloxacin, and trovafloxacin and nonquinolones linozelid, quinupristin-dalfopristin, gentamicin, and vancomycin against clinical isolates of ciprofloxacin-resistant and -susceptible Staphylococcus aureus strains.
Jones ME; Visser MR; Klootwijk M; Heisig P; Verhoef J; Schmitz FJ
Antimicrob Agents Chemother; 1999 Feb; 43(2):421-3. PubMed ID: 9925551
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
